EAN 2022 | Benefits of personalized extended interval dosing of natalizumab

Extended interval dosing of natalizumab has been proposed as a way to maintain its efficacy while reducing exposure to it. Alyssa Toorop, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, outlines the benefits of personalized extended interval dosing of natalizumab in patients with multiple sclerosis (MS). Evidence suggests that patients on an extended interval dosing have a lower risk of developing progressive multifocal leukoencephalopathy. Additionally, since patients don’t need to get natalizumab infusions so often, it leads to fewer hospital visits and a decrease in healthcare costs. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.